Inauguring webinar of the CASE Direct series
About this event
Every year, we watch world-class clinical trial presentations at ASCO and ESMO and appreciate the marvelous works done by leading global Principal Investigators (PI). As a professional in clinical trial space, do you want to learn what’s behind the success of these clinical trials and these masters? Have you also dreamt of just being like them and present your own clinical research results on ASCO and ESMO?
eChinaHealth and AOCRAS jointly launch the “CASE Direct” series webinars of world-class clinical trials case analysis. We borrow from case study methods prevailing in business schools, to dissect deeply on global clinical trials, and dialogue directly with the prominent global PI of these trials, to explore the "insider story and secret recipes” behind these global clinical trials and the masters.
The hottest area of drug development in recent years is the research and development of ADC drugs. There is not only the spectacular 226 million yuan failure of Bio-Thera's clinical trial, but also the amazing glory of RemeGen's $2.6 billion global licensing of its ADC drug. Nevertheless, the brightest star in the ADC field is undoubtedly the impeccable DESTINY series clinical trial and amazing results of Enhertu (DS-8201), developed by Daiichi Sankyo.
Our Inauguring webinar of the CASE Direct series focuses on DESTINY-Gastric case study and a direct dialogue with the trail PI, Dr. Kohei Shitara of Japan Cancer Center Hospital. Our second webinar focuses on DESTINEY-Breast03 case study and a direct dialogue with the trail PI, Dr. Sara Hurvitz of PI University of California, Los Angeles.
Webinar Agenda
Welcome Remarks:
• Dr. Jianqiang Cai, Deputy Director of China National Cancer Center
CASE Analysis：DESTINY-Gastric trial
• Dr. Sheng Luo, Duke University
• Dr. Kohei Shitara, Japan Cancer Center Hospital
Panelists：
• Dr. Hong Zhao, Cance
r Hospital, Chinese Academy of Medical Sciences
• Dr. Ying Yuan, MD Anderson Cancer Center
• Dr. Tang Li, St. Jude Children’s Research Hospital
Closing Summary：
• Dr. Sheng Luo, Duke University
Our Speakers
• Dr. Jianqiang Cai, Deputy Director of China National Cancer Center
Professional Societies: Stan
ding Member, Oncology branch of Chinese Medical Association Vice Director, Experts Committee on Liver Cancer, The Chinese Medical Doctor Association Vice Director, Experts Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases, Chinese Preventive Medicine Association Director, Experts Committee on Sarcoma, Chinese Anti-Cancer Association Chief Editor, Electronic Journal of Liver Tumor Magazine
Professional Direction: Comprehensive treatment of abdominal tumors and translational medicine research.
• Dr. Sheng Luo, Duke University
Dr. Luo is professor of Biostatistics & Bioinformatics at Duke University. He received his PhD in Biostatistics from The Johns Hopkins University. He is Fellow of American Statistical Association (ASA) and Elected Member of International Statistical Institute. Dr. Luo is a leading expert in statistical methods of the design and analysis of clinical trials and observational studies. He has more than 100 peer-reviewed articles published in high-impact clinical and statistical journals. Dr. Luo has served as PI of multiple NIH grants on statistical methodology development. He is also PI of multiple projects regarding novel latent variable modeling and various neurodegenerative disorders rating scale development, validation, and translation funded by Parkinson’s Foundation, CHDI Foundation, and Movement Disorders Society.
• Dr. Kohei Shitara, Japan Cancer Center Hospital
Dr Kohei Shitara is a Chief of Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa in Japan.
He received his medical degree from Tohoku University School of Medicine in 2002. Dr Shitara is an active member of ASCO and ESMO. He is also a member of the Japanese Society of Internal Medicine, the Japanese Society of Medical Oncology (JSMO), the Japanese Society of Clinical Oncology (JSCO), and the Japanese Gastric Cancer Association. He also acts as one of the organising members for Japanese gastric cancer treatment guidelines.
Main research interests include development of new anti-cancer agents, optimal chemotherapy regimen for gastrointestinal cancer, and translational research. He is the primary investigator or study coordinator of several sponsor initiated trials or investigator initiated trials for gastric or colorectal cancer: He act as one of steering committee members of several ongoing global studies in the field of GI cancers.
• Dr. Hong Zhao, Cancer Hospital, Chinese Academy of Medical Sciences
Vice Director & Professor, Department of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences
Zhao Hong is Vice Director of Department of Hepatobiliary Surgery and Laboratory of abdominal surgical oncology in Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College. He is also Professor of Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College. He graduated from the Chinese Peking Union Medical College received his MD in 2003.
Professional direction: surgical treatment of colorectal cancer liver metastasis, neuroendocrine tumor, hepatocellular carcinoma.
Professional Societies: Secretary General of Neuroendocrine Tumor Society, China International Exchange and Promotive Association for Medical and Health Care, Member of Advisory Board of ENETS, Member of Chinese Association of Young Scientists And Technologists, Member of liver metastasis committee, colorectal Society, Chinese Anti-Cancer Association, Member of Colorectal Cancer Liver Metastasis Society, China International Exchange and Promotive Association for Medical and Health Care, Deputy Chair of Youth scholar committee, Oncology Society of Beijing
Medical Association, Secretary General of Youth scholar committee of Liver cancer Society, China
International Exchange and Promotive Association for Medical and Health Care.
• Dr. Ying Yuan, MD Anderson Cancer Center
Ying Yuan, PhD, is a Bettyann Asche Murray Distinguished Professor and Deputy Chair in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. Dr. Yuan has published over 100 statistical methodology papers on innovative Bayesian adaptive designs, including early phase trials, seamless trials, biomarker-guided trials, and basket and platform trials. The designs and software developed by Dr. Yuan’s lab (www.trialdesign.org) have been widely used in medical research institutes and pharmaceutical companies. Dr. Yuan is the Chair of Data Safety Monitoring Board (DSMB), overseeing over 100 ongoing randomized clinical trials at MD Anderson Cancer Center. Dr. Yuan was elected as the American Statistical Association Fellow and wrote book “Bayesian Designs for Phase I-II Clinical Trials” published by Chapman & Hall/CRC.
• Dr. Tang Li, St. Jude Children’s Research Hospital
Dr. Li Tang is an Associate Member in the Department of Biostatistics at St. Jude Children's Research Hospital. She is the Associate Director of the National Cancer Institute (NCI)-funded Biostatistics Shared Resource (BSR) of St. Jude. Every year, the BSR at St. Jude has over 100 clinical studies either in design and development, active accrual or analysis stages at any given time. Dr. Tang has extensive experience and research expertise in the design and analysis of clinical trials and clinical observational studies. As part of her methodology research, Dr. Tang focuses on new methods and their applications to data arising from pediatric oncology studies and from emerging infectious diseases research, including microbiome analysis and predictive analytics.
Comments